Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Advanced Melanoma

Journal Scan / Research · August 18, 2022

Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on PD-1/PD-L1 Inhibitor–Based Therapies

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
J. Clin. Oncol 2022 Jul 22;[EPub Ahead of Print], A Arance, L de la Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, A Berrocal, I Márquez-Rodas, A Spreafico, V Atkinson, F Costa Svedman, A Mant, MA Khattak, C Mihalcioiu, S Jang, CL Cowey, AD Smith, N Hawk, K Chen, SJ Diede, C Krepler, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading